First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients ...
Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...
With $202.3M in cash and an expanded $125M debt facility, ENGN is financially equipped to advance pivotal Cohort 1 and pursue ...
The TAR-200 system offering sustained intravesical gemcitabine release shows favorable response and tolerability in both the CIS and papillary-only subgroups with BCG-unresponsive high-risk NMIBC. TAR ...
ScRNA-seq profiles to identify HES1 associated with ACTH-secreting tumors and the distinct microenvironment between ACTH+/CRH+ and ACTH-/CRH- pheochromocytomas. This is an ASCO Meeting Abstract from ...
The FDA approved a gemcitabine intravesical system (Inlexzo) for adults with non-muscle-invasive bladder cancer (NMIBC), the agency announced on Tuesday. The indication for the chemotherapy-containing ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results